← Back to all trials
Recruiting
NCT07843225
Standard Closure vs. Integrated Mesh-Fascial Closure (IMFC) for Incisional Hernia Repair
Conditions: Incisional Hernia Repair, Ventral Incisional Hernia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Hospital Zonal General De Agudos Mario V Larrain
Location: Hospital Zonal General de Agudos "Dr. Mario V. Larrain Berisso Buenos Aires
Summary
This study compares two surgical techniques for closing the abdominal wall in adult patients who have an incisional hernia (a weakness or opening in a previous surgical incision) or who require prophylactic mesh placement during a laparotomy.
In one group, the abdominal wall is closed using the standard technique, in which a polypropylene mesh is fixed independently from the fascial suture. In the other group, a new technique called Integrated Mesh-Fascial Closure (IMFC), developed by the research team, is used: the mesh is incorporated directly within the same continuous suture line that closes the abdominal wall, aiming to better distribute tension across the surgical wound.
The choice of technique is made by the patient after receiving information about both options and providing informed consent. Participants will be followed clinically and with imaging for 18 to 24 months to evaluate the safety, technical feasibility, and reproducibility of the IMFC technique, and to determine the incidence of hernia recurrence in both groups.
Eligibility Criteria
Inclusion Criteria:
* Adults older than 18 years of age
* Patients with incisional (ventral) hernia
* Patients with recurrent incisional hernia
* Incisional hernias with a diameter greater than 4 cm
* Patients undergoing laparotomy with an indication for prophylactic mesh placement
Exclusion Criteria:
* Active surgical site infection
* Overt abdominal contamination
* Tissue necrosis or inability to achieve primary fascial closure
* Non-correctable loss of domain
* Pregnant women or women of childbearing potential planning pregnancy or not using contraception during the follow-up period
* Patients belonging to vulnerable populations, in accordance with Law 15.462 and applicable ethical guidelines
* Active oncologic disease (patients with a cured oncologic history may be included)
Source: ClinicalTrials.gov (NCT07843225). StuddyBuddy aggregates publicly available trial information.